Skip to main content
Premium Trial:

Request an Annual Quote

Maxygen Signs Research Agreement with NCI, Files For Second Stock Offering

Premium

R

EDWOOD CITY, Calif.--Maxygen announced that it has signed a Cooperative Research and Development Agreement with the US National Cancer Institute for pharmaceutical protein development. In the three-year deal, the company will apply its MolecularBreed-ing directed evolution technologies to the development of novel protein pharmaceuticals for cancer treatments. NCI will provide expertise in characterizing and evaluating the proteins for therapeutic potential. The specific target proteins and indications were not disclosed.

Separately, Maxygen filed with the US Securities and Exchange Commission to sell 1.5 million shares of common stock in what will be its second public offering. Maxygen went public last December with an offering of 6.9 million shares at $16 each, resulting in net proceeds of $102 million.

Filed under

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.